Abstract
The synthesis of dipyrazolo[1,5-a:4',3'-c]pyridines is described. Easily obtainable 5-alkynylpyrazole-4-carbaldehydes, p-toluenesulfonyl hydrazide, and an aldehyde or ketone containing an α-hydrogen atom were reacted in a silver triflate catalyzed multicomponent reaction affording new tricyclic compounds with a dipyrazolo[1,5-a:4',3'-c]pyridine core. Detailed NMR spectroscopic investigations (1H, 13C and 15N) were undertaken with all obtained compounds.
Graphical Abstract
Introduction
Condensed pyrazole scaffolds are important substructures of compounds with biological activity and can be found in some well-known drug molecules, such as, for example, Sildenafil (a pyrazolo[4,3-d]pyrimidine) [1,2], Allopurinol (a pyrazolo[3,4-d]pyrimidin-4-one) [3], Zaleplon (a pyrazolo[1,5-a]pyrimidine) [4], and Zolazepam (a pyrazolo[3,4-e][1,4]diazepine derivative, used in veterinary medicine) [5]. Particularly pyrazolopyrimidines are a very frequently accessed class of compounds [6] with the particular importance of the pyrazolo[3,4-d]pyrimidine core, which can closely mimic the purine system of adenosine and, thus, has been incorporated in various compounds impairing protein kinases and ATPases [7-9]. Moreover, a large variety of additional fused pyrazoles exhibit interesting biological activities, such as, pyrazolo[1,5-a]quinolones [10], pyrazolo[4,3-c]quinolones [11], pyrazolo[5,1-a]isoquinolines [12], and thieno[2,3-c]pyrazoles [13]. In view of these facts as well as due to our continuing interest in the exploration of useful but unused chemical space, which has become a paradigm of contemporary medicinal chemistry [14], we have devoted some effort to the construction of novel condensed heterocyclic systems containing pyrazole substructures. Apart from a series of publications dealing with the construction of pyrazole analogues of xanthones and related systems [15-20] we recently described the synthesis of pyrano[4,3-c]pyrazol-4(1H)-ones and -4(2H)-ones [21], 1,5-dihydro- resp. 2,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-ones [20], and pyrazolo[4,3-c]pyridines [22]. In continuation of these studies we herein present the synthesis and detailed NMR spectroscopic characterization of the new heterocyclic system dipyrazolo[1,5-a:4',3'-c]pyridine. The access to the latter was achieved by a multicomponent reaction (MCR) starting from 5-alkynylpyrazole-4-carbaldehydes. Such MCRs, although being present since the early days of organic chemistry, nowadays attract an increasing interest because of their unmatched synthetic efficiency, which permits the construction of complex molecules in an elegant and sufficient manner [23-26].
Results and Discussion
Chemistry
The starting compounds for the construction of the title compounds are the 5-alkynylpyrazole-4-carbaldehydes 1. Their synthesis from easily accessible 2-pyrazolin-5-ones through Vilsmeier formylation (with concomitant transformation of the oxygen into a chlorine substituent), followed by Sonogashira cross-coupling reaction of the obtained 5-chloropyrazole-4-carbaldehydes with appropriate alkynes, has been described by us in a former publication [21]. Compounds 1 containing an alkyne function and a nucleophilic substituent in the ortho position of the pyrazole system are valuable precursors for the construction of corresponding annulated systems. In order to employ this arrangement of functionalities for the latter purpose, we adapted the approach of Wu and co-workers, who described the synthesis of H-pyrazolo[5,1-a]isoquinolines by a one-pot tandem reaction of 2-alkynylbenzaldehydes, sulfonohydrazide, and ketones or aldehydes [27]. In our case, application of pyrazolecarbaldehydes 1 should enable access to the desired dipyrazolo[1,5-a:4',3'-c]pyridines 5.
In order to test the reaction conditions, firstly each step of the multicomponent reaction was carried out separately. According to the strategy, pyrazole-4-carbaldehyde 1a was primarily condensed with p-toluenesulfonyl hydrazide affording hydrazide 2a in 97% yield (Scheme 1). Secondly, two steps of the applied strategy were performed at once: condensation of 1a with p-toluenesulfonyl hydrazide and subsequent 6-endo-dig cyclization [28] of intermediate 2a in the presence of silver triflate produced p-toluenesulfonylazamide 3a in 91% yield (Scheme 1). The reaction of intermediate 3a with CH-acidic aldehydes or ketones in the presence of base would lead to various dipyrazolo[1,5-a:4',3'-c]pyridines 5.
Scheme 1: Intermediate reactions of pyrazole-4-carbaldehyde 1a.
Scheme 1: Intermediate reactions of pyrazole-4-carbaldehyde 1a.
Thus, after these results, we decided to explore the one-pot tandem reaction with various 5-alkynylpyrazole-4-carbaldehydes 1, p-toluenesulfonyl hydrazide and butyraldehyde (4a). As alkynyl functions, phenylethynyl (1a,b), 3-thienylethynyl (1c,d) and hex-1-ynyl (1e,f) were employed; silver triflate was used as the catalyst and K3PO4 as a base, needed for the formation of the second pyrazole ring. In this way, the dipyrazolo[1,5-a:4',3'-c]pyridines 5a–f were achieved in yields of 44–83% (Table 1, entries 1–6). Replacement of butyraldehyde by propionaldehyde (4b) or 3-phenylpropanal (4c) afforded the corresponding tricyclic products 5g, 5h and 5i in 59–73% yield, respectively (Table 1, entries 7–9). Lastly, application of the cyclic ketones cyclopentanone (4d), cyclohexanone (4e) and 2-methylcyclohexanone (4f) as carbonyl components resulted in the formation of tetracycles 5j–l in acceptable yields (Table 1, entries 10–12).
Table 1: Multicomponent reaction of various 5-alkynyl-1-phenyl-1H-pyrazole-4-carbaldehydes 1 with p-toluenesulfonyl hydrazide and aldehydes or ketones 4.
|
||||
Entry | Compound 1 | Compound 4 | Product 5 | Yield, % |
---|---|---|---|---|
1 |
1a |
4a |
5a |
83 |
2 |
1b |
4a |
5b |
47 |
3 |
1c |
4a |
5c |
73 |
4 |
1d |
4a |
5d |
73 |
5 |
1e |
4a |
5e |
44 |
6 |
1f |
4a |
5f |
79 |
7 |
1a |
4b |
5g |
59 |
8 |
1a |
4c |
5h |
73 |
9 |
1b |
4c |
5i |
59 |
10 |
1a |
4d |
5j |
46 |
11 |
1a |
4e |
5k |
64 |
12 |
1a |
4f |
5l |
38 |
NMR spectroscopic investigations
The NMR spectroscopic data of all compounds described in this study are given in Supporting Information File 1. Unequivocal assignment of resonances was carried out by the combined application of various standard NMR spectroscopic techniques, such as 1H coupled 13C NMR spectra, APT, HMQC, gs-HSQC, gs-HMBC, COSY, TOCSY, NOESY and NOE-difference spectroscopy [29]. In some cases experiments with selective excitation of certain 1H resonances were performed, such as long-range INEPT [30] and 2D(δ,J) long-range INEPT [31], the latter experiments having been used for the unambiguous determination of long-range 13C,1H coupling constants.
With compound 2a, the tosylhydrazone of starting aldehyde 1a, (E)-configuration at the C=N double bond follows from an NOE between the iminyl-H (7.96 ppm) and NH (8.22 ppm) as well from the size of 1J(N=C–H) (160.7 Hz). In contrast, the (Z)-configuration and thus cis-position of the lone pair of the nitrogen and the coupled proton with respect to the C=N double bond should result in a considerably larger 1J-coupling due to lone-pair effects, which strongly influence such spin couplings [32,33].
The target products 5a–l show very consistent signal sets regarding the invariable part of the molecules. In the 1H NMR spectra of congeners unsubstituted at position 1 (5b, 5d, 5f, 5i) the signals due to H-1 and H-4 are split due to a small long-range coupling (5J(H-1,H-4) ~ 0.8 Hz). The signal of H-4 is located within a relatively small range, namely between 6.85 and 7.20 ppm. Those compounds unsubstituted at position 8 show the H-8 signal at 7.75–7.91 ppm. Characteristic core signals in the 13C NMR spectra are those of C-3a (134.8–136.7 ppm), C-4 (95.1–98.3 ppm), C-9 (5j: C-10a, 5k,l: C-11a) (105.6–114.6 ppm), C-9a (5j: C-10b, 5k,l: C-11b) (130.4–134.2) and C-9b (5j: C-10c, 5k,l: C-11c) (111.2–112.7 ppm). The other carbon resonances (C-1, C-5, C-8) are influenced by the attached substituents to a somewhat larger extent. Also the 15N NMR spectra show a uniform pattern: the resonances of N-2 and N-3 are slightly influenced by the substituent at position 1 with the 1-H derivatives having slightly larger chemical shifts than those of the corresponding 1-methyl congeners. The 15N chemical shifts of N-6 and N-7 are somewhat smaller with derivatives 5j–5l having a cycloaliphatic ring anellated to the concerning pyrazole ring. In Figure 1 the 1H, 13C and 15N NMR chemical shifts are displayed for model compound 5d, for which also the numbering of ring atoms is given.
Figure 1: 1H NMR (in italics), 13C NMR and 15N NMR (in bold) chemical shifts of 5d in CDCl3 solution (with numbering of ring atoms).
Figure 1: 1H NMR (in italics), 13C NMR and 15N NMR (in bold) chemical shifts of 5d in CDCl3 solution (with nu...
The obtained NMR spectroscopic data are inasmuch valuable as the availability of reliable, unambiguously assigned chemical shift data is important as reference material for NMR prediction programs, such as CSEARCH/NMRPREDICT [34,35] or ACD/C+H predictor [36]. Such programs have become more and more popular in the past few years, particularly for the prediction of 13C NMR chemical shifts. However, the quality of such predictions is highly dependent on the disposability of authentic reference data of related structures, a criterion which is frequently not fulfilled for rare or new condensed heterocyclic systems, such as those described here.
Conclusion
In conclusion, we present a simple and nonlaborious method to access dipyrazolo[1,5-a:4',3'-c]pyridines from easily obtainable 5-alkynyl-1-phenyl-1H-pyrazole-4-carbaldehydes through a silver triflate catalyzed one-pot tandem reaction with p-toluenesulfonyl hydrazide and an appropriate aldehyde or ketone. Moreover, the novel heterocyclic system was investigated in great detail by extensive NMR spectroscopic investigations including also 15N. Further studies to exploit the synthetic potential as well as the biological activities of the latter compounds are in progress and will be published elsewhere.
Supporting Information
Supporting Information File 1: Experimental details and characterization data. | ||
Format: PDF | Size: 230.3 KB | Download |
References
-
Kleemann, A.; Engel, J.; Kutscher, B.; Reichert, D. Pharmaceutical Substances, 3rd ed.; Georg Thieme Verlag: Stuttgart/New York, 1999; pp 1725–1727.
Return to citation in text: [1] -
Boolell, M.; Gepi-Attee, S.; Gingell, J. C.; Allen, M. J. Br. J. Urol. 1996, 78, 257–261. doi:10.1046/j.1464-410X.1996.10220.x
Return to citation in text: [1] -
Pacher, P.; Nivorozhkin, A.; Szabó, C. Pharmacol. Rev. 2006, 58, 87–114. doi:10.1124/pr.58.1.6
Return to citation in text: [1] -
Elie, R.; Ruther, E.; Farr, I.; Emilien, G.; Salinas, E. J. Clin. Psychiatry 1999, 60, 526–544. doi:10.4088/JCP.v60n0806
Return to citation in text: [1] -
DeWald, H. A.; Lobbestael, S.; Butler, D. E. J. Med. Chem. 1977, 20, 1562–1569. doi:10.1021/jm00222a005
Return to citation in text: [1] -
Singh, S.; Sharma, P. K.; Dudhe, R.; Kumar, N. Pharma Sci. Monit. 2011, 2, 131–144.
Return to citation in text: [1] -
Radi, M.; Dreassi, E.; Brullo, C.; Crespan, E.; Tintori, C.; Bernardo, V.; Valoti, M.; Zamperini, C.; Daigl, H.; Musumeci, F.; Carraro, F.; Naldini, A.; Filippi, I.; Maga, G.; Schenone, S.; Botta, M. J. Med. Chem. 2011, 54, 2610–2626. doi:10.1021/jm1012819
Return to citation in text: [1] -
Honigberg, L. A.; Smith, A. M.; Sirisawad, M.; Verner, E.; Loury, D.; Chang, B.; Li, S.; Pan, Z.; Thamm, D. H.; Miller, R. A.; Buggy, J. J. Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 1375–1380. doi:10.1073/pnas.1004594107
Return to citation in text: [1] -
Evans, L. E.; Cheeseman, M. D.; Jones, K. Org. Lett. 2012, 14, 3546–3549. doi:10.1021/ol301561a
Return to citation in text: [1] -
Barrett, D.; Sasaki, H.; Kinoshita, T.; Fujikawa, A.; Sakane, K. Tetrahedron 1996, 52, 8471–8488. doi:10.1016/0040-4020(96)00415-2
Return to citation in text: [1] -
Mekheimer, R. A.; Ahmed, E. A.; Sadek, K. U. Tetrahedron 2012, 68, 1637–1667. doi:10.1016/j.tet.2011.10.088
Return to citation in text: [1] -
Chen, Z.; Wu, J. Org. Lett. 2010, 12, 4856–4859. doi:10.1021/ol101988q
Return to citation in text: [1] -
Tonani, R.; Bindi, S.; Fancelli, D.; Pittala, V.; D’Anello, M. Heterobicyclic Pyrazole Derivatives as Kinase Inhibitors. U.S. Patent 20060160874, July 20, 2006.
Return to citation in text: [1] -
Marson, C. M. Chem. Soc. Rev. 2011, 40, 5514–5533. doi:10.1039/c1cs15119c
Return to citation in text: [1] -
Eller, G. A.; Wimmer, V.; Haring, A. W.; Holzer, W. Synthesis 2006, 4219–4229. doi:10.1055/s-2006-950324
Return to citation in text: [1] -
Eller, G. A.; Haring, A. W.; Datterl, B.; Zwettler, M.; Holzer, W. Heterocycles 2007, 71, 87–104. doi:10.3987/COM-06-10908
Return to citation in text: [1] -
Eller, G. A.; Holzer, W. Molecules 2007, 12, 60–73. doi:10.3390/12010060
Return to citation in text: [1] -
Eller, G. A.; Datterl, B.; Holzer, W. J. Heterocycl. Chem. 2007, 44, 1139–1143. doi:10.1002/jhet.5570440526
Return to citation in text: [1] -
Eller, G. A.; Zhang, Q.; Habicht, D.; Datterl, B.; Holzer, W. Acta Chim. Slov. 2009, 56, 521–526.
Return to citation in text: [1] -
Eller, G. A.; Habicht, D.; Holzer, D. Chem. Heterocycl. Compd. 2008, 44, 709–714. doi:10.1007/s10593-008-0106-5
Return to citation in text: [1] [2] -
Arbačiauskienė, E.; Vilkauskaitė, G.; Šačkus, A.; Holzer, W. Eur. J. Org. Chem. 2011, 1880–1890. doi:10.1002/ejoc.201001560
Return to citation in text: [1] [2] -
Vilkauskaitė, G.; Šačkus, A.; Holzer, W. Eur. J. Org. Chem. 2011, 5123–5133. doi:10.1002/ejoc.201100626
Return to citation in text: [1] -
Isambert, N.; Lavilla, R. Chem.–Eur. J. 2008, 14, 8444–8454. doi:10.1002/chem.200800473
Return to citation in text: [1] -
Müller, T. J. J. Beilstein J. Org. Chem. 2011, 7, 960–961. doi:10.3762/bjoc.7.107
Return to citation in text: [1] -
Zhu, J.; Bienaymé, H., Eds. Multicomponent Reactions; Wiley-VCH: Weinheim, Germany, 2005. doi:10.1002/3527605118
Return to citation in text: [1] -
Dömling, A.; Ugi, I. Angew. Chem., Int. Ed. 2000, 39, 3168–3210. doi:10.1002/1521-3773(20000915)39:18<3168::AID-ANIE3168>3.0.CO;2-U
Return to citation in text: [1] -
Yu, X.; Ye, S.; Wu, J. Adv. Synth. Catal. 2010, 352, 2050–2056. doi:10.1002/adsc.201000176
Return to citation in text: [1] -
Baldwin, J. E.; Thomas, R. C.; Kruse, L. I.; Silberman, L. J. Org. Chem. 1977, 42, 3846–3852. doi:10.1021/jo00444a011
Return to citation in text: [1] -
Braun, S.; Kalinowski, H.-O.; Berger, S. 150 and More Basic NMR Experiments, 2nd ed.; Wiley-VCH: Weinheim, New York, 1998.
Return to citation in text: [1] -
Bax, A. J. Magn. Reson. 1984, 57, 314–318.
Return to citation in text: [1] -
Jippo, T.; Kamo, O.; Nagayama, N. J. Magn. Reson. 1986, 66, 344–348.
Return to citation in text: [1] -
Gil, V. M. S.; von Philipsborn, W. Magn. Reson. Chem. 1989, 27, 409–430. doi:10.1002/mrc.1260270502
Return to citation in text: [1] -
Heinisch, G.; Holzer, W. Monatsh. Chem. 1990, 121, 837–846. doi:10.1007/BF00808377
Return to citation in text: [1] -
Kalchhauser, H.; Robien, W. J. Chem. Inf. Comput. Sci. 1985, 25, 103–108. doi:10.1021/ci00046a010
Return to citation in text: [1] -
NMR Predict, 4.7; Modgraph Consultants, Ltd.: Herts, UK, 2010, http://www.modgraph.co.uk/product_nmr.htm.
Return to citation in text: [1] -
ACD/C+H Predictors and DB, 10.04; Advanced Chemistry Development, Inc.: Toronto, ON, Canada, 2006, http://www.acdlabs.com.
Return to citation in text: [1]
1. | Kleemann, A.; Engel, J.; Kutscher, B.; Reichert, D. Pharmaceutical Substances, 3rd ed.; Georg Thieme Verlag: Stuttgart/New York, 1999; pp 1725–1727. |
2. | Boolell, M.; Gepi-Attee, S.; Gingell, J. C.; Allen, M. J. Br. J. Urol. 1996, 78, 257–261. doi:10.1046/j.1464-410X.1996.10220.x |
6. | Singh, S.; Sharma, P. K.; Dudhe, R.; Kumar, N. Pharma Sci. Monit. 2011, 2, 131–144. |
22. | Vilkauskaitė, G.; Šačkus, A.; Holzer, W. Eur. J. Org. Chem. 2011, 5123–5133. doi:10.1002/ejoc.201100626 |
5. | DeWald, H. A.; Lobbestael, S.; Butler, D. E. J. Med. Chem. 1977, 20, 1562–1569. doi:10.1021/jm00222a005 |
23. | Isambert, N.; Lavilla, R. Chem.–Eur. J. 2008, 14, 8444–8454. doi:10.1002/chem.200800473 |
24. | Müller, T. J. J. Beilstein J. Org. Chem. 2011, 7, 960–961. doi:10.3762/bjoc.7.107 |
25. | Zhu, J.; Bienaymé, H., Eds. Multicomponent Reactions; Wiley-VCH: Weinheim, Germany, 2005. doi:10.1002/3527605118 |
26. | Dömling, A.; Ugi, I. Angew. Chem., Int. Ed. 2000, 39, 3168–3210. doi:10.1002/1521-3773(20000915)39:18<3168::AID-ANIE3168>3.0.CO;2-U |
4. | Elie, R.; Ruther, E.; Farr, I.; Emilien, G.; Salinas, E. J. Clin. Psychiatry 1999, 60, 526–544. doi:10.4088/JCP.v60n0806 |
21. | Arbačiauskienė, E.; Vilkauskaitė, G.; Šačkus, A.; Holzer, W. Eur. J. Org. Chem. 2011, 1880–1890. doi:10.1002/ejoc.201001560 |
3. | Pacher, P.; Nivorozhkin, A.; Szabó, C. Pharmacol. Rev. 2006, 58, 87–114. doi:10.1124/pr.58.1.6 |
20. | Eller, G. A.; Habicht, D.; Holzer, D. Chem. Heterocycl. Compd. 2008, 44, 709–714. doi:10.1007/s10593-008-0106-5 |
11. | Mekheimer, R. A.; Ahmed, E. A.; Sadek, K. U. Tetrahedron 2012, 68, 1637–1667. doi:10.1016/j.tet.2011.10.088 |
15. | Eller, G. A.; Wimmer, V.; Haring, A. W.; Holzer, W. Synthesis 2006, 4219–4229. doi:10.1055/s-2006-950324 |
16. | Eller, G. A.; Haring, A. W.; Datterl, B.; Zwettler, M.; Holzer, W. Heterocycles 2007, 71, 87–104. doi:10.3987/COM-06-10908 |
17. | Eller, G. A.; Holzer, W. Molecules 2007, 12, 60–73. doi:10.3390/12010060 |
18. | Eller, G. A.; Datterl, B.; Holzer, W. J. Heterocycl. Chem. 2007, 44, 1139–1143. doi:10.1002/jhet.5570440526 |
19. | Eller, G. A.; Zhang, Q.; Habicht, D.; Datterl, B.; Holzer, W. Acta Chim. Slov. 2009, 56, 521–526. |
20. | Eller, G. A.; Habicht, D.; Holzer, D. Chem. Heterocycl. Compd. 2008, 44, 709–714. doi:10.1007/s10593-008-0106-5 |
10. | Barrett, D.; Sasaki, H.; Kinoshita, T.; Fujikawa, A.; Sakane, K. Tetrahedron 1996, 52, 8471–8488. doi:10.1016/0040-4020(96)00415-2 |
7. | Radi, M.; Dreassi, E.; Brullo, C.; Crespan, E.; Tintori, C.; Bernardo, V.; Valoti, M.; Zamperini, C.; Daigl, H.; Musumeci, F.; Carraro, F.; Naldini, A.; Filippi, I.; Maga, G.; Schenone, S.; Botta, M. J. Med. Chem. 2011, 54, 2610–2626. doi:10.1021/jm1012819 |
8. | Honigberg, L. A.; Smith, A. M.; Sirisawad, M.; Verner, E.; Loury, D.; Chang, B.; Li, S.; Pan, Z.; Thamm, D. H.; Miller, R. A.; Buggy, J. J. Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 1375–1380. doi:10.1073/pnas.1004594107 |
9. | Evans, L. E.; Cheeseman, M. D.; Jones, K. Org. Lett. 2012, 14, 3546–3549. doi:10.1021/ol301561a |
13. | Tonani, R.; Bindi, S.; Fancelli, D.; Pittala, V.; D’Anello, M. Heterobicyclic Pyrazole Derivatives as Kinase Inhibitors. U.S. Patent 20060160874, July 20, 2006. |
28. | Baldwin, J. E.; Thomas, R. C.; Kruse, L. I.; Silberman, L. J. Org. Chem. 1977, 42, 3846–3852. doi:10.1021/jo00444a011 |
21. | Arbačiauskienė, E.; Vilkauskaitė, G.; Šačkus, A.; Holzer, W. Eur. J. Org. Chem. 2011, 1880–1890. doi:10.1002/ejoc.201001560 |
27. | Yu, X.; Ye, S.; Wu, J. Adv. Synth. Catal. 2010, 352, 2050–2056. doi:10.1002/adsc.201000176 |
34. | Kalchhauser, H.; Robien, W. J. Chem. Inf. Comput. Sci. 1985, 25, 103–108. doi:10.1021/ci00046a010 |
35. | NMR Predict, 4.7; Modgraph Consultants, Ltd.: Herts, UK, 2010, http://www.modgraph.co.uk/product_nmr.htm. |
36. | ACD/C+H Predictors and DB, 10.04; Advanced Chemistry Development, Inc.: Toronto, ON, Canada, 2006, http://www.acdlabs.com. |
32. | Gil, V. M. S.; von Philipsborn, W. Magn. Reson. Chem. 1989, 27, 409–430. doi:10.1002/mrc.1260270502 |
33. | Heinisch, G.; Holzer, W. Monatsh. Chem. 1990, 121, 837–846. doi:10.1007/BF00808377 |
29. | Braun, S.; Kalinowski, H.-O.; Berger, S. 150 and More Basic NMR Experiments, 2nd ed.; Wiley-VCH: Weinheim, New York, 1998. |
© 2012 Holzer et al; licensee Beilstein-Institut.
This is an Open Access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The license is subject to the Beilstein Journal of Organic Chemistry terms and conditions: (http://www.beilstein-journals.org/bjoc)